12.10.2012 - Dutch Royal DSM collaborates with a Sanofi subsidiary to stretch ist algal expression system into animal health vaccine production.
This strategic alliance could change the established ways of vaccine production. DSM Nutritional Product, a subsidiary of Dutch Royal DSM N.V., has announced a Development and Option to License Agreement with animal health specialist Merial Limited, part of the US-subsidiary of French Sanofi S.A. The partners want to bring together their expertise to produce animal health vaccines in DSM’s proprietary algal expression system. Compared to existing techniques based on eggs or cell cultures, the new platform could present a faster and more efficient production method. Financial details were not disclosed. It is known, however, that Merial will provide R&D funding to value DSM’s research efforts. DSM would also be eligible to receive milestone payments, license fees and royalties on sales of a successfully launched product.
Almost two years ago Royal DSM acquired Martek Biosciences Corporation from Columbia (Maryland, USA) in a billion dollar deal. This marked DSM’s transformation into a life sciences and materials sciences company. In Columbia omega-3- and omega-6-products are produced by algae. Former Martek CEO Peter Nitze, now President of the Nutritional Lipids division of DSM Nutritional Products, welcomes the expansion of the algae-production portfolio: „We are pleased to join Merial on this important project that we expect will validate the algal expression system as a viable alternative to known vaccine production methods.“ DSM is better known as a global player in biofuel production. The company hit the news earlier this year when it announced the start of a joint venture with US-ethanol producer POET, LLC.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.